CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Raltegravir

Last Updated: December 4, 2009
Result type: Reports
Project Number: S0191
Product Line: Common Drug Review

Generic Name: Raltegravir

Brand Name: Isentress

Manufacturer: Merck Frosst Canada Ltd.

Indications: HIV (treatment naïve)

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: June 23, 2010

Recommendation Type: Do not list